P689: UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapyECCO '18 Vienna
2018
P690: Clinical and endoscopic outcomes of one year golimumab treatment in patients with active ulcerative colitis: A real-life observational studyECCO '18 Vienna
2018
P691: Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52ECCO '18 Vienna
2018
P692: Efficacy and safety of early biologic treatment of Crohn’s disease in adult and paediatric patients: A systematic reviewECCO '18 Vienna
2018
P693: Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?ECCO '18 Vienna
2018
P694: Non-medical mandatory reversed and back and forth switch between infliximab and its biosimilar: Early clinical outcomesECCO '18 Vienna
2018
P695: Does anticoagulation treatment increase the rate of major bleeding complications in patients with IBD and venous thromboembolism?ECCO '18 Vienna
2018
P696: Faecal microbiota transplantation in ultra-refractory ulcerative colitis: Retrospective analysis in a tertiary care centreECCO '18 Vienna
2018
P697: Thiopurines vs. anti-TNFa for the prevention of postoperative recurrence in Crohn’s disease—a meta-analysisECCO '18 Vienna
2018
P698: Early dose optimisation in non-responders to golimumab induction treatment for ulcerative colitis is supported by pharmacokinetic dataECCO '18 Vienna
2018
P699: Radiologic response reduces the risk of small-bowel surgery in Crohn’s diseaseECCO '18 Vienna
2018
P700: A high CRP before surgery and early medical prophylaxis predict postoperative endoscopic Crohn’s disease recurrenceECCO '18 Vienna
2018
P701: Quality of life of patients with inflammatory bowel diseases who live with an ostomy: Results of a French national surveyECCO '18 Vienna
2018
P703: Clinical, radiographic and endoscopic remission with vedolizumab treatment in Crohn’s diseaseECCO '18 Vienna
2018
P704: Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn’s diseaseECCO '18 Vienna
2018
P705: Switching from originator to biosimilar infliximab—real-world data from 18 months prospective follow-up of a single-centre IBD populationECCO '18 Vienna
2018
P706: Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapyECCO '18 Vienna
2018